ENDRA posts strong TAEUS Liver study data, showing high measurement reliability for MASLD monitoring and boosting its ...
ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for the ...
Quibim, a global company pioneering imaging biomarkers for precision medicine, is today announcing the launch of a new product, QP-Liver, which improves the diagnosis of diffuse liver diseases through ...
Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ANN ARBOR, ...
A form of MRI technology can quantify liver response in patients with nonalcoholic steatohepatitis, according to recent research by the University of California San Diego School of Medicine. Here’s ...
New findings from the DIRECT PLUS, 18-month-long lifestyle intervention trial underscores the potential to observe and signify alterations of MRI-assessed liver fat with proteomics according to new ...
WASHINGTON & OXFORD, England--(BUSINESS WIRE)--Perspectum announced two research studies that were recently published, bringing hope to people with metabolic dysfunction-associated steatohepatitis ...
PET-CT imaging with [18 F]fluorodeoxyglucose (FDG) and [18 F]fluorocholine (FCH) altered treatment plans in only a tiny minority of patients undergoing initial staging for hepatocellular carcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results